Palexia (Tapentadol)

Tapentadol, the active ingredient in Palexia, is an opioid analgesic presented as a strength/form for oral use. It is indicated for the management of moderate to severe acute pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Palexia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Tapentadol is an opioid analgesic that acts within the central nervous system to relieve pain.

- Acute postoperative pain: provides effective relief when non‑opioid analgesics are insufficient. - Chronic musculoskeletal pain: helps reduce pain intensity in conditions such as osteoarthritis. - Neuropathic pain associated with diabetic peripheral neuropathy: alleviates burning and shooting pain sensations. - Cancer‑related pain: contributes to multimodal pain control in oncology patients. - Severe trauma pain: offers strong analgesia during the acute phase of injury.

Tapentadol may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea - Constipation - Dizziness - Somnolence - Headache - Dry mouth

Serious or Rare Side Effects: - Respiratory depression - Seizures - Severe hypotension - Serotonin syndrome - Allergic reactions such as rash or angio‑edema - Dependence or abuse potential

When prescribing Tapentadol, clinicians should consider several safety aspects.

- Assess pain severity and prior opioid use: ensure appropriate indication before initiating therapy. - Monitor for respiratory depression: especially during dose titration or in patients with pulmonary disease. - Evaluate renal and hepatic function: dose adjustments may be required in impairment. - Avoid concomitant CNS depressants: increased risk of sedation and respiratory effects. - Counsel patients on signs of dependence: educate about proper use and storage. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Tapentadol can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: risk of hypertensive crisis or serotonin syndrome. - CNS depressants (benzodiazepines, barbiturates): heightened respiratory depression. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase tapentadol plasma levels.

Moderate Interactions (Monitor Closely): - Serotonergic agents (SSRIs, SNRIs, tramadol): potential for serotonin syndrome. - Antihypertensives: additive hypotensive effect. - Diuretics: may exacerbate orthostatic hypotension.